A detailed history of Morgan Stanley transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 49,012 shares of HOWL stock, worth $103,905. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,012
Previous 20,579 138.17%
Holding current value
$103,905
Previous $133,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.34 - $6.75 $66,533 - $191,922
28,433 Added 138.17%
49,012 $119,000
Q1 2024

Aug 16, 2024

BUY
$3.92 - $7.91 $78,317 - $158,033
19,979 Added 3329.83%
20,579 $133,000
Q1 2024

May 15, 2024

BUY
$3.92 - $7.91 $78,317 - $158,033
19,979 Added 3329.83%
20,579 $133,000
Q4 2023

Aug 16, 2024

SELL
$1.78 - $4.15 $86,173 - $200,909
-48,412 Reduced 98.78%
600 $2,000
Q4 2023

Feb 13, 2024

SELL
$1.78 - $4.15 $3,382 - $7,885
-1,900 Reduced 76.0%
600 $2,000
Q1 2023

May 15, 2023

SELL
$1.98 - $4.3 $23 - $51
-12 Reduced 0.48%
2,500 $6,000
Q4 2022

Feb 14, 2023

SELL
$1.53 - $4.73 $12,201 - $37,721
-7,975 Reduced 76.05%
2,512 $5,000
Q3 2022

Nov 14, 2022

SELL
$4.14 - $7.42 $48,847 - $87,548
-11,799 Reduced 52.94%
10,487 $47,000
Q2 2022

Oct 27, 2022

BUY
$3.43 - $5.98 $50,270 - $87,642
14,656 Added 192.08%
22,286 $91,000
Q2 2022

Aug 15, 2022

BUY
$3.43 - $5.98 $50,270 - $87,642
14,656 Added 192.08%
22,286 $91,000
Q1 2022

Oct 27, 2022

SELL
$3.71 - $12.22 $54,373 - $179,096
-14,656 Reduced 65.76%
7,630 $33,000
Q1 2022

May 13, 2022

SELL
$3.71 - $12.22 $1,606 - $5,291
-433 Reduced 5.37%
7,630 $33,000
Q4 2021

Feb 14, 2022

BUY
$11.48 - $17.65 $75,182 - $115,589
6,549 Added 432.56%
8,063 $96,000
Q3 2021

Nov 15, 2021

BUY
$13.89 - $20.31 $21,029 - $30,749
1,514 New
1,514 $26,000

Others Institutions Holding HOWL

About Werewolf Therapeutics, Inc.


  • Ticker HOWL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,529,400
  • Market Cap $62.6M
  • Description
  • Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...
More about HOWL
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.